Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to researchers.
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to researchers.